Topical vaginal drug therapy in cervical cancer management: a review of clinical trials and preclinical evidence.
Li C, Zhu Y, Li N, Dai B, Wang J, Wang L, Wang LL, Zheng X.
Li C, et al.
Med Oncol. 2025 Oct 17;42(11):523. doi: 10.1007/s12032-025-02983-z.
Med Oncol. 2025.
PMID: 41107612
Review.
Cervical cancer, the fourth most prevalent malignancy among women globally, is predominantly caused by persistent infection with high-risk human papillomavirus (HPV). Traditional methods such as surgery and chemotherapy are often associated with high incidence of ad …
Cervical cancer, the fourth most prevalent malignancy among women globally, is predominantly caused by persistent infection with high-risk h …